SenzaGen: €2.4m

Case

“At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds. The grant we have received will be the perfect catalyst for this vision. We will use the funding to bring an innovative product to the market, with potential to become the cornerstone of our long-term competitiveness. For a small life science company, a grant covering 100 % of the project costs is of unparalleled value. We would like to thank GAEU for supporting us to secure this grant. We have received excellent guidance and advice in the application process. The team responsible for our proposal was easy to work with and very knowledgeable. GAEU is an excellent Horizon 2020 advisor and long term business partner.”

- Anki Malmborg Hager CEO

Previous
Previous

CombiGene AB (publ): €3.3m

Next
Next

Corline Biomedical AB (publ): €2.3m